Sponsor & Developer Portfolio
Bavarian Nordic
Clinical development pipeline, platform architecture, and registered trial tracking for Bavarian Nordic vaccine candidates.
5
Candidates
4
Target Diseases
5
Linked Studies
Development Phase Distribution
Discontinued / Inactive: 2 Phase 2 Clinical Trial: 2 Phase 3 Clinical Trial: 1
Platform Technologies
Biological (unspecified platform): 4 Protein / subunit: 1
Target Pathogens & Indications
Chikungunya Encephalitis Mpox RSV
Vaccine Pipeline Candidates (5)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Discontinued / Inactive
ctgov-mva-bn-rsv-bavarian-nordic
MVA-BN-RSV
Target: RSV
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2017-10-27 (registry estimate)
Discontinued / Inactive
ctgov-mva-bn-rsv-vaccine-bavarian-nordic
MVA-BN-RSV vaccine
Target: RSV
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2023-06-29 (registry estimate)
Phase 2 Clinical Trial
ctgov-jynneos-bavarian-nordic
Jynneos
Target: Mpox
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2026-11-30 (registry estimate)
Phase 2 Clinical Trial
ctgov-mva-bn-wev-bavarian-nordic
MVA-BN-WEV
Target: Encephalitis
Platform: Protein / subunit
Key Milestone: Primary completion (most advanced trial): 2027-02 (registry estimate)
Phase 3 Clinical Trial
ctgov-chikv-vlp-vaccine-booster-bavarian-nordic
Placebo booster
Target: Chikungunya
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2028-04 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.